Liposomal amphotericin B related late-onset hyperphosphatemia in a pediatric patient with acute myeloid leukemia

Çifci S. A., Yalçın N., Aksu T., Demirkan K.

Journal of Oncology Pharmacy Practice, cilt.28, sa.6, ss.1478-1482, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Sayı: 6
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1177/10781552221077051
  • Dergi Adı: Journal of Oncology Pharmacy Practice
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
  • Sayfa Sayıları: ss.1478-1482
  • Anahtar Kelimeler: Amphotericin B, electrolyte abnormalities, hyperphosphatemia, liposomal amphotericin B, pediatric hematology, PSEUDOHYPERPHOSPHATEMIA
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Introduction: Children with acute myeloid leukemia (AML) are at risk for serious electrolyte abnormalities. Case report: We reported a case of hyperphosphatemia in a child with acute myeloid leukemia who received liposomal amphotericin B (AMBL) for the treatment of an invasive fungal infection. The findings of this case suggest that cumulative dose accumulation due to long term AMBL treatment may result in late-onset hyperphosphatemia. Management and outcome: This is the first case report in the literature that of late-onset hyperphosphatemia (day 56) in a patient with low-dose AMBL treatment (3–5 mg/kg/day) and normal renal function. Discussion: We highlight the importance of increasing awareness of AMBL related hyperphosphatemia among healthcare providers.